0001127602-20-017235.txt : 20200519 0001127602-20-017235.hdr.sgml : 20200519 20200519171048 ACCESSION NUMBER: 0001127602-20-017235 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200515 FILED AS OF DATE: 20200519 DATE AS OF CHANGE: 20200519 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Burke William P. Mr. CENTRAL INDEX KEY: 0001682069 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14041 FILM NUMBER: 20894641 MAIL ADDRESS: STREET 1: HAEMONETICS CORPORATION STREET 2: 400 WOOD ROAD CITY: BRAINTREE STATE: MA ZIP: 02184 FORMER NAME: FORMER CONFORMED NAME: Burke Willaim P DATE OF NAME CHANGE: 20160810 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HAEMONETICS CORP CENTRAL INDEX KEY: 0000313143 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042882273 STATE OF INCORPORATION: MA FISCAL YEAR END: 0328 BUSINESS ADDRESS: STREET 1: 125 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 7818487100 MAIL ADDRESS: STREET 1: 125 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02110 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2020-05-15 0000313143 HAEMONETICS CORP HAE 0001682069 Burke William P. Mr. 125 SUMMER STREET BOSTON MA 02110 1 EVP, Chief Financial Officer Common Stock 2020-05-15 4 S 0 221 100.44 D 10190 D Common Stock 2020-05-18 4 A 0 3144 A 13334 D Non-qualified Stock Option (Right to Buy) 103.37 2020-05-18 4 A 0 10639 0 A 2027-05-18 Common Stock 10639 10639 D Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This number includes unvested RSUs previously reported. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. /s/ Thomas V. Powers, attorney-in-fact for Mr. Burke 2020-05-19